The safety and efficacy of oral levocarnitine have not been demonstrated in patients with renal insufficiency
*Correspondence: Hitoshi Ando, [email protected] This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
To make the current evidence and gaps explicit, we now include Table 2 summarizing representative ferroptosis-in-AD studies (human, animal, and cellular), indicating which hallmarks were examined and whether selective rescue or checkpoint linkage was established (Li et al., 2022
However, as with any medical therapy, there may be situations where discontinuing the medication becomes necessary or desirable
The total cost should thus be put into consideration and budgeted for properly